57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.
44 citations
,
April 2006 in “Expert opinion on drug safety” This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.
36 citations
,
January 2012 in “Dermatology” This case report describes how discontinuing the EGFR inhibitor gefitinib led to rapid improvement of erosive scalp pustules in a woman with non-small-cell lung cancer, despite previous antibiotic and steroid treatment failures.
21 citations
,
June 2017 in “Case Reports in Dermatology” This case report describes a 57-year-old Japanese female who developed scarring alopecia linked to gefitinib, an EGFR inhibitor, with improvement in hair loss after reducing the drug dosage.
7 citations
,
January 2009 in “BMJ Case Reports” This report describes a rare case of a non-small-cell lung cancer patient experiencing hair changes after prolonged gefitinib treatment, potentially linked to EGFR inhibition, with limited understanding of its cause.